Skip to main content
Figure 3 | Arthritis Research & Therapy

Figure 3

From: MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments

Figure 3

Peripheral blood CD4 expression and CD4 occupancy. Mean changes in peripheral blood CD4 expression and CD4 occupancy on memory (CD45RA-) CD4 T cells in patients receiving placebo or MTRX1011A in the single dose (A and C) and multiple dose (B and D) phase of the study when administered intravenously (IV) or subcutaneously (SC) at doses ranging from 0.3 to 7 mg/kg. A and B, MTRX1011A treatment induced a dose dependent down modulation of CD4 expression on peripheral blood memory CD4 T cells. C and D, MTRX1011A administration resulted in a dose dependent occupancy of CD4 sites on peripheral blood memory CD4 T cells.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us